Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Mortality in renal cell cancer (RCC) is high in the elderly population. Comorbidities have a greater impact on overall prognosis of RCC among elderly patients than in younger patients. All new RCC cases were collected in people over 74 years of age between 1995 and 2018 from the Finnish cancer registry. The comorbidities were identified from the Care Registry for Healthcare. Charlson Comorbidity Index (CCI) was used to evaluate the risk of death based on comorbidities. The overall risk of death was analyzed using the Cox regression model. The risk for RCC death was analyzed using Fine and Gray regression analysis. Individual prognostic role of CCI components was evaluated by adding each component separately into the multivariable Fine and Gray regression model. Using the most prognostic comorbidities we constructed a nomogram to predict RCC mortality. Statistically significant prognostic factors of RCC death were tumor morphology (clear cell, papillary and chromophobe), sex, operative treatment, age, primary tumor extent and CCI. The strongest prognostic factors for overall mortality were tumor extent, tumor morphology and operative treatment. Among the components of CCI, the most important comorbidities predicting mortality were dementia, heart failure and kidney disease. The limitation of this study is that the comorbidities have only been recorded at inpatient and outpatient hospital contacts, which is why the prevalence of comorbidities is probably underestimated. In addition, physical performance status was not available from registry data, but it significantly affects the treatment decisions. RCC mortality is high in the elderly population. Among comorbidities, dementia and heart failure have the greatest impact on the prognosis. Curative treatment in selected elderly patients is efficient and should be considered in patients who can tolerate it and have only limited comorbidities.
Mortality in renal cell cancer (RCC) is high in the elderly population. Comorbidities have a greater impact on overall prognosis of RCC among elderly patients than in younger patients. All new RCC cases were collected in people over 74 years of age between 1995 and 2018 from the Finnish cancer registry. The comorbidities were identified from the Care Registry for Healthcare. Charlson Comorbidity Index (CCI) was used to evaluate the risk of death based on comorbidities. The overall risk of death was analyzed using the Cox regression model. The risk for RCC death was analyzed using Fine and Gray regression analysis. Individual prognostic role of CCI components was evaluated by adding each component separately into the multivariable Fine and Gray regression model. Using the most prognostic comorbidities we constructed a nomogram to predict RCC mortality. Statistically significant prognostic factors of RCC death were tumor morphology (clear cell, papillary and chromophobe), sex, operative treatment, age, primary tumor extent and CCI. The strongest prognostic factors for overall mortality were tumor extent, tumor morphology and operative treatment. Among the components of CCI, the most important comorbidities predicting mortality were dementia, heart failure and kidney disease. The limitation of this study is that the comorbidities have only been recorded at inpatient and outpatient hospital contacts, which is why the prevalence of comorbidities is probably underestimated. In addition, physical performance status was not available from registry data, but it significantly affects the treatment decisions. RCC mortality is high in the elderly population. Among comorbidities, dementia and heart failure have the greatest impact on the prognosis. Curative treatment in selected elderly patients is efficient and should be considered in patients who can tolerate it and have only limited comorbidities.
Renal cell carcinoma (RCC) is a common and aggressive form of kidney cancer, with genetic factors playing a significant role in its development. Recent research has focused on the potential involvement of cytokine gene polymorphisms, including those in the interleukin (IL) -13 gene, in RCC susceptibility. The present study aimed to investigate the association between the IL-13 gene rs20541 single nucleotide polymorphism (SNP) and the risk of RCC in Iraqi patients. Methods. A case-control study was conducted involving 250 participants, including 125 patients diagnosed with RCC and 125 healthy controls matched for age and sex. Blood samples were collected from all participants for DNA extraction. The IL-13 gene rs20541 SNP was genotyped using the Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction (TARMS-PCR) method. Statistical analysis was performed to compare the frequencies of genotypes (GG, GA, AA) and alleles (G, A) between cases and controls, and to evaluate their association with RCC risk. Results. The study found significant differences in the distribution of IL-13 rs20541 genotypes and alleles between RCC patients and healthy controls. The presence of the GG genotype was significantly associated with an increased risk of RCC (OR = 3.7, 95% CI = 2.15–6.37, P = 0.002), while the AA genotype was significantly associated with a protective effect against the disease (OR = 0.38, 95% CI = 0.21–0.69, p = 0.002). On the other hand, the GA genotype did not show a significant association with protection against RCC (OR = 0.6, 95% CI = 0.36–1.00, p = 0.067). For the G and A alleles, the G allele was found to be a highly significant risk factor for RCC (OR = 2.67, 95% CI = 1.85–3.84, p <0.0001), while the A allele was significantly associated with a protective effect (OR = 0.37, 95% CI = 0.26–0.54, p <0.0001). Conclusion. The current study provides evidence that the IL-13 rs20541 SNP, particularly the GG genotype and G allele, may be associated with an increased risk of developing RCC in the Iraqi population. This finding suggests that the rs20541 polymorphism could serve as a potential genetic marker for RCC susceptibility. Further research is needed to confirm these results and to explore the underlying mechanisms of how IL-13 gene polymorphisms contribute to RCC pathogenesis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.